

Published in final edited form as:

Nat Genet. ; 43(10): 969–976. doi:10.1038/ng.940.

Genome-wide association study identifies five new schizophrenia loci

© 2011 Nature America, Inc. All rights reserved.

¹A full list of authors and affiliations appears at the end of the paper.

Note: Supplementary information is available on the Nature Genetics website.

AUTHOR CONTRIBUTIONS

The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium (PGC): **overall coordination:** P.V.G. **Coordination of statistical analyses:** M.J.D. **Coordination of phenotypic analyses:** K.S.K. **Statistical analyses:** S.R., M.J.D., P.A.H., D.-Y.L., S.P., F.D., B.M.N., L.R., P.M.V., D.P., D.M.R. **Manuscript preparation:** P.V.G. (primary), M.J.D. (primary), A.R.S. (primary), S.R. (primary), M.C.O. (primary), K.S.K., D.F.L., P.S., P.A.H., P.F.S. (primary), D.-Y.L., J.D., R.A.O., O.A.A., E. Scolnick. **Phenotypic analyses:** K.S.K., A.F., A.C., R.L.A. **Stage 1 GWAS sample 1–Cardiff, UK:** M.C.O., N.C., P.A.H., M. Hamshere, H.J.W., V. Moskvina, S. Dwyer, L.G., S.Z., M.J.O. **Stage 1 GWAS sample 2–Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE):** P.F.S., D.-Y.L., E.v.d.O., Y.K., T.S.S., J.A.L. **Stage 1 GWAS sample 3–International Schizophrenia Consortium (ISC)–Aberdeen:** D.St.C. **Stage 1 GWAS sample 4–ISC–Cardiff:** G.K.K., M.C.O., P.A.H., L.G., I.N., H.J.W., D.T., V. Milanova, M.J.O. **Stage 1 GWAS sample 5–ISC–Dublin:** D.W.M., C.T.O., E.K., E.M.Q., M.G., A.C. **Stage 1 GWAS sample 6–ISC–Edinburgh:** D.H.R.B., K.A.M., B.P., P. Malloy, A.W.M., A. McIntosh. **Stage 1 GWAS sample 7–ISC–London:** A. McQuillin, K.C., S. Datta, J.P., S. Thirumalai, V.P., R.K., J. Lawrence, D.Q., N.B., H.G. **Stage 1 GWAS sample 8–ISC–Portugal:** M.T.P., C.N.P., A.F. **Stage 1 GWAS sample 9–ISC–SW1–Sweden, stage 1 GWAS sample 10–ISC–SW2–Sweden, stage 2 replication follow-up sample 16–SW3–Sweden, stage 2 replication follow-up sample 17–SW4–Sweden:** C.M.H., P.L., S.E.B., S.P., E. Scolnick, P.S., P.F.S. **Stage 1 GWAS sample 11–Molecular Genetics of Schizophrenia (MGS):** J. Shi, D.F.L., J.D., A.R.S., M.C.K., B.J.M., A.O., F.A., C.R.C., J.M.S., N.G.B., W.F.B., D.W.B., K.S.K., R.F., P.V.G. **Stage 1 GWAS sample 12–Schizophrenia Genetics Consortium (SGENE)–Bonn:** S.C., M. Rietschel, M.M.N., W.M., T.G.S., M. Mattheisen. **Stage 1 GWAS sample 13–SGENE–Copenhagen, stage 2 replication follow-up sample 5–SGENE–Copenhagen:** T.H., A.I., K.D.J., L.D., G.J., H.B.R., B.G., J.N., S. Timm, L.O., A.G.W., A.F.-J., J.H.T., T.W. **Stage 1 GWAS sample 14–SGENE–Munich, stage 2 replication follow-up sample 12–SGENE–Munich, stage 2 replication follow-up sample 13–SGENE–Munich:** I.G., A.M.H., H.K., M.F., B.K., P. Muglia, D.R. **Stage 1 GWAS sample 15–SGENE–Thematic Organized Psychoses Research 3 (TOP3):** S. Djurovic, M. Mattingsdal, I.A., I.M., O.A.A. **Stage 1 GWAS sample 16–SGENE–UCLA:** R.A.O., R.M.C., N.B.F., R.S.K., D.H.L., J.v.O., D. Wiersma, R.B., W.C., L.d.H., L.K., I.M.-G., E. Strengman. **Stage 1 GWAS sample 17–Zucker Hillside:** A.K.M., T.L. **Stage 2 replication follow-up sample 1–multicenter pedigree:** P.A.H., B.P.R., A.E.P., M.J.O., D.B.W., P.V.G., B.J.M., C.L., K.S.K., G.N., N.M.W., S.G.S., A.R.S., M. Hansen, D.A.N., J.M., B.W., V.K.L., M.C.O., J.D., M. Albus, M. Alexander, S.G., R.R., K.-Y.L., N.N., W.M., G.P., D. Walsh, M.J., F.A.O., F.B.L., D. Dikeos, J.M.S., D.F.L. **Stage 2 replication follow-up sample 2–SGENE–Aarhus:** A.D.B., D. Demontis, P.B.M., D.M.H., T.F.Ø., O.M. **Stage 2 replication follow-up sample 3–SGENE–Aarhus:** O.M., M.N., A.D.B. **Stage 2 replication follow-up sample 4–SGENE–Belgium:** R.v.W., G.K., M.D.H., J.V. **Stage 2 replication follow-up sample 6–SGENE–Iceland:** H.S., S.S., E. Sigurdsson, H.P., K.S. **Stage 2 replication follow-up sample 7–SGENE–England:** D.A.C. **Stage 2 replication follow-up sample 8–SGENE–Helsinki, stage 2 replication follow-up sample 11–SGENE–Kuusamo:** L.P., O.P.H.P., J. Suvisaari, J. Lönqvist. **Stage 2 replication follow-up sample 9–SGENE–Hungary:** I.B., J.M.R. **Stage 2 replication follow-up sample 10–SGENE–Italy:** M. Ruggeri, S. Tosato. **Stage 2 replication follow-up sample 14–SGENE–Russia:** V.G. **Stage 2 replication follow-up sample 15–SGENE–Sweden:** E.G.J., I.A., L.T. **Stage 2 replication follow-up sample 18–University of Queensland:** B.J.M., M.A.B., P.A.D., J.J.M., D.E.M. **Stage 2 replication follow-up sample 18–Australian Schizophrenia Research Bank:** B.J.M., V.J.C., R.J.S., S.V.C., F.A.H., A.V.J., C.M.L., P.T.M., C.P., U.S. **Stage 2 replication follow-up sample 19–Irish Schizophrenia Genomics Consortium (ISGC):** A.C., D.W.M., P.C., B.S.M., C.T.O., G.D., F.A.O., M.G., K.S.K., B.P.R., ISGC (see the Acknowledgments in the Supplementary Note for additional contributors not listed above). **Stage 2 replication follow-up sample 19–Wellcome Trust Case Control Consortium 2 (WTCCC2):** P.D. (Chair of Management Committee; Data and Analysis Group), C.C.A.S. (Data and Analysis Group; Publications Committee), A.S. (Data and Analysis Group), WTCCC2 (see Acknowledgments in the Supplementary Note for additional contributors not listed above). All authors contributed to the current version of the paper.

COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details accompany the full-text HTML version of the paper at <http://www.nature.com/naturegenetics/>.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

²⁰Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, Germany.

³⁰Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research, Manhasset, New York, USA.

¹¹⁶Department of Psychiatry, University of Erlangen-Nuremberg, Erlangen, Germany.

The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium¹

Abstract

We examined the role of common genetic variation in schizophrenia in a genome-wide association study of substantial size: a stage 1 discovery sample of 21,856 individuals of European ancestry and a stage 2 replication sample of 29,839 independent subjects. The combined stage 1 and 2 analysis yielded genome-wide significant associations with schizophrenia for seven loci, five of which are new (1p21.3, 2q32.3, 8p23.2, 8q21.3 and 10q24.32-q24.33) and two of which have been previously implicated (6p21.32-p22.1 and 18q21.2). The strongest new finding ($P = 1.6 \times 10^{-11}$) was with rs1625579 within an intron of a putative primary transcript for *MIR137* (microRNA 137), a known regulator of neuronal development. Four other schizophrenia loci achieving genome-wide significance contain predicted targets of *MIR137*, suggesting *MIR137*-mediated dysregulation as a previously unknown etiologic mechanism in schizophrenia. In a joint analysis with a bipolar disorder sample (16,374 affected individuals and 14,044 controls), three loci reached genome-wide significance: *CACNA1C* (rs4765905, $P = 7.0 \times 10^{-9}$), *ANKK1* (rs10994359, $P = 2.5 \times 10^{-8}$) and the *ITIH3-ITIH4* region (rs2239547, $P = 7.8 \times 10^{-9}$).

In stage 1, we conducted a mega-analysis combining genome-wide association study (GWAS) data from 17 separate studies (with a total of 9,394 cases and 12,462 controls; Table 1 and Supplementary Tables 1,2). We imputed allelic dosages for 1,252,901 autosomal SNPs (Table 1, Supplementary Table 3 and Supplementary Note) using HapMap3 as the reference panel¹. We tested for association using logistic regression of imputed dosages with sample identifiers and three principal components as covariates to minimize inflation in significance testing caused by population stratification. The quantile-quantile plot (Supplementary Fig. 1) deviated from the null distribution with a population stratification inflation factor of $\lambda = 1.23$. However, λ_{1000} , a metric that standardizes the degree of inflation by sample size, was only 1.02, similar to that observed in other GWAS meta-analyses^{2,3}. This deviation persisted despite comprehensive quality control and inclusion of up to 20 principal components (Supplementary Fig. 1). Thus, we interpret this deviation as indicative of a large number of weakly associated SNPs consistent with polygenic inheritance⁴. We also examined 298 ancestry-informative markers (AIMs) that reflect European-ancestry population substructure⁵. Unadjusted analyses showed greater inflation in the test statistics than we saw for all markers (AIMs $\lambda = 2.26$ compared to all markers $\lambda = 1.56$). After inclusion of principal components, the distributions of the test statistics did not differ between AIMs ($\lambda = 1.18$) and all markers ($\lambda = 1.23$), a result inconsistent with population stratification explaining the residual deviation seen in Supplementary Figure 1. Moreover, the results of a meta-analysis using summary results generated using study specific principal components (Supplementary Note) were highly correlated with those from the mega-analysis (Pearson correlation = 0.94, with a similar $\lambda = 1.20$; Supplementary Fig. 2). Of the ten SNPs in Table 2, four increased and six decreased in significance, suggesting that the most extreme values did not result from systematic inflation artifacts. Therefore, our primary analysis used unadjusted P values (nevertheless, see Table 2 for stage 1 P values adjusted for λ (ref. 6).

In stage 1 (Table 2, Supplementary Table 4 and Supplementary Figs. 3 and 4), 136 associations reached genome-wide significance ($P < 5 \times 10^{-8}$)⁷. The majority of these associations ($N = 129$) mapped to 5.5 Mb in the extended major histocompatibility complex (MHC, 6p21.32-p22.1), a region of high linkage disequilibrium (LD) previously implicated in schizophrenia in a subset of the samples used here^{4,8,9}. The other stage 1 regions included new regions (10q24.33 and 8q21.3) and previously reported regions (18q21.2 at *TCF4* encoding transcription factor 4) and 11q24.2 (ref. 8)). The signal at 11q24.2 is ~0.85 Mb

from *NRGN* (encoding neurogranin) and is uncorrelated with the previously associated variant near this gene⁸.

In Table 2 and Supplementary Table 4, we denote regions of association by the most significant marker. Associated SNPs with $r^2 \geq 0.2$ in HapMap3 (CEU+TSI populations) were not considered independent. However, we noticed instances where multiple SNPs within 250 kb of each other yielded evidence for association ($P < 10^{-5}$) despite weak LD ($r^2 < 0.2$) between them. For regions with $P < 10^{-6}$, we performed a conditional analysis using as covariates the dosages of the strongest associated SNP, principal components 1–4 and 6 and study indicator. We observed multiple statistically independent signals at the MHC. Although a number of SNPs within the MHC were potentially independent per HapMap r^2 values, only rs9272105 withstood formal conditional analysis, showing $P = 1.8 \times 10^{-6}$ conditional on association to the best SNP, rs2021722 (stage 1 $P = 4.3 \times 10^{-11}$, inter-SNP distance = 2.4 Mb, $r^2 = 0.01$ in HapMap). Excluding the MHC region, we identified six regions with at least one SNP associated at $P < 10^{-5}$ and a second SNP with a conditionally independent $P < 10^{-3}$ (Supplementary Table 5). We performed 100 simulations after permuting case-control status randomly within each study. In contrast to the six regions in the real dataset, we never observed more than a single region with co-localized statistically independent signals in any simulated genome-wide scan, indicating our observation is highly unlikely to have occurred by chance.

Noteworthy co-localizing independent signals occurred at three regions (Supplementary Table 5): one region with a genome-wide significant association at 10q24.32-q24.33 (Table 2), a second region that nearly met this threshold at *MADILI* (encoding mitotic arrest deficient-like 1; rs10226475, $P = 5.06 \times 10^{-8}$; Supplementary Table 4) and a third region at *CACNA1C* (encoding calcium channel, voltage-dependent, L type, α 1C subunit), the latter of which has previously been associated with bipolar disorder¹⁰ and other psychiatric phenotypes including schizophrenia¹¹. The conditionally independent signal at *CACNA1C* was more significant than any observation made in 100 permutations of the entire experiment (both conditional $P < 10^{-5}$) and supports *CACNA1C* in schizophrenia after genome-wide correction ($P < 0.01$), even without considering these prior reports.

In stage 2, we evaluated in 29,839 independent subjects (8,442 cases and 21,397 controls) the most significant SNPs ($N = 81$) in each LD region where at least one SNP had surpassed $P < 2 \times 10^{-5}$ (Supplementary Table 6) in the mega-analysis. Of 22 SNPs from the MHC, 5 surpassed the genome-wide significant threshold in stages 1 and 2 combined (minimum $P = 2.2 \times 10^{-12}$ at rs2021722; Supplementary Table 6). Excluding the MHC region, a sign test for consistency between stages 1 and 2 was highly significant ($P < 10^{-6}$), with the same direction of effect as observed stage 1 also being observed in stage 2 for 49 of 59 SNPs. A Fisher's combined test revealed the distribution of stage 2 P values was unlikely to have occurred by chance ($P < 10^{-15}$). We also performed a transmission analysis using the family based Multicenter Pedigree replication sample in conjunction with a GWAS of 622 parent-offspring schizophrenia trios from Bulgaria¹², and the stage 1 associated allele was over-transmitted to cases for 44 of the 59 SNPs (one-sided $P = 1.0 \times 10^{-4}$). Thus, the stage 2 replication results are highly consistent with the stage 1 discovery results.

In the combined dataset (stages 1 and 2), five new (1p21.3, 2q32.3, 8p23.2, 8q21.3 and 10q24.32-q24.33) and two previously reported (6p21.32-p22.1 and 18q21.2) loci met genome-wide significance (Figs. 1,2, Table 2, Supplementary Tables 6,7 and Supplementary Fig. 4). After adjusting for λ (ref. 6), four loci (1p21.3, 6p21.32-p22.1, 10q24.32-q24.33 and 18q21.2) remained significant at $P \leq 5 \times 10^{-8}$. For the primary analyses (unadjusted for λ), the strongest new association was at 1p21.3 (rs1625579; $P = 1.6 \times 10^{-11}$), which is over 100 kb from any RefSeq protein-coding gene but is within intron 3 of AK094607, which

contains the primary transcript for *MIR137* (ref. 13). The next best locus, 10q24.32 (Supplementary Table 5 and Supplementary Fig. 5), has independent associations 130 kb apart at rs7914558 ($P = 1.8 \times 10^{-9}$) and rs11191580 ($P = 1.1 \times 10^{-8}$), implicating a 0.5-Mb region containing multiple genes (Supplementary Fig. 5). The third best locus, rs7004633 ($P = 2.8 \times 10^{-8}$) on 8q21.3, is 400 kb from the nearest gene (*MMP16*, encoding matrix metalloproteinase 16). The fourth best locus, rs10503253 ($P = 4.4 \times 10^{-8}$) at 8p23.2, is in an intron of *CSMD1* (encoding CUB and Sushi multiple domains 1). Finally, rs17662626 ($P = 4.7 \times 10^{-8}$) at 2q32.3 is intergenic, mapping 300 kb from a non-coding RNA, *PCGEM1* (prostate-specific transcript 1)¹⁴.

MIR137 has been implicated in regulating adult neurogenesis^{15,16} and neuronal maturation¹⁷, mechanisms through which variation at this locus could contribute to brain development abnormalities in schizophrenia. Of relevance, two independent schizophrenia imaging studies found *MIR137* to be one of three microRNAs with targets significantly enriched for association¹⁸. In stage 1, SNPs in or near 301 high-confidence predicted *MIR137* targets (with a TargetScan¹⁹ probability of conserved targeting ≥ 0.9) were enriched for association compared with genes matched for size and marker density: 17 predicted *MIR137* targets (Supplementary Table 8) had at least one SNP with $P < 10^{-4}$, which is more than twice as many as the control gene sets ($P < 0.01$). Excluding the MHC and *MIR137*, of the nine loci with genome-wide significant support either in stage 1 or in the combined set (six loci, 2q32.3, 8p23.2, 8q21.3, 10q24.32-q24.33, 11q24.2 and 18q21.2; Table 2 and Supplementary Tables 6,7) or in a joint analysis with bipolar disorder (three genes, *CACNA1C*, *ANK3* and *ITIH3-ITIH4*, described below), four genes (*TCF4*, *CACNA1C*, *CSMD1* and *C10orf26*) have predicted *MIR137* target sites according to analyses using three different prediction programs (TargetScan¹⁹, PicTar²⁰ and miRanda²¹). *In vitro* overexpression and locked nucleic acid-mediated knockdown of *MIR137* in neuronal cell line N2a leads to changes in expression levels of TCF4 protein, strongly supporting the prediction that *TCF4* is a target of *MIR137* (L.-H. Tsai, personal communication). Our observations suggest *MIR137*-mediated dysregulation as a new etiologic mechanism in schizophrenia.

The International Schizophrenia Consortium (ISC) reported evidence for a polygenic contribution to schizophrenia⁴. An independent family based study confirmed these results, greatly minimizing the possibility of population stratification artifact¹². We reevaluated the polygenic model, dividing stage 1 samples into independent training and testing sets (Supplementary Note). The training set had 15,429 subjects (over twice the size of the ISC training set), and the testing set consisted of 6,428 individuals independent of the ISC report. The proportion of variance (Nagelkerke's r^2) explained in the testing set increased from 3% in the ISC to around 6% here (Supplementary Table 9 and Supplementary Fig. 6). This estimate is much lower than the true total variation in liability that is tagged by all SNPs because SNP effects are estimated with error^{3,4,22-25}. The polygenic model appears to explain a substantial fraction of the heritability of schizophrenia⁴, as has been shown for other complex traits^{3,26-28}. Some of these additional risk loci are likely contained near the most highly significant results of our stage 1 analysis. Supporting this hypothesis, of the top loci that did not reach genome-wide significance in the combined stage 1 and 2 analysis, a sign test ($P < 10^{-4}$) and a Fisher's combined test ($P < 10^{-5}$) both showed an excess of same-direction allelic association (41 of 51 non-MHC SNPs) in the discovery and replication datasets.

Clinical, epidemiological and genetic findings suggest shared risk factors between bipolar disorder and schizophrenia²⁹. In stage 1, three genes with strong support had prior genome-wide significant associations with bipolar disorder: *CACNA1C*, the region containing *ITIH3-ITIH4* (encoding inter- α (globulin) inhibitors H3 and H4) and *ANK3* (encoding ankyrin 3,

node of Ranvier (ankyrin G)^{10,11,30} (Supplementary Table 10). We performed a joint analysis with the Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium (PGC) for bipolar disorder applying identical analytical methods. After removing duplicate subjects, we analyzed 16,374 cases with schizophrenia, schizoaffective disorder or bipolar disorder and 14,044 controls. Support for shared susceptibility was strengthened (Supplementary Table 11) at *CACNA1C* (rs4765905, $P = 7.0 \times 10^{-9}$), *ANK3* (rs10994359, $P = 2.5 \times 10^{-8}$) and the *ITIH3-ITIH4* region (rs2239547, $P = 7.8 \times 10^{-9}$), each of which reached genome-wide significance. A coding variant in *ITIH4* (p.Pro698Thr; rs4687657) is in perfect LD with the most associated SNP. Although we included all subjects from an earlier report¹⁰, the increased support found with additional independent cases ($N = 11,987$) and controls ($N = 7,835$) provides further evidence for shared risk effects of schizophrenia and bipolar disorder.

The risk variants implicated here confer small risks (odds ratios ~ 1.10), but the polygenic analysis shows many more susceptibility variants with effects for which our sample is underpowered (Supplementary Table 12). At every stage where samples were added, we found an increase in the number of genome-wide significant loci and enhancement of signals at *CACNA1C*, *ANK3* and *ITIH3-ITIH4* when schizophrenia and bipolar disorder were jointly analyzed. Thus, gains in power offset any penalty for increased heterogeneity.

In summary, we report seven genome-wide significant schizophrenia associations (five of which are new) in a two-stage analysis of 51,695 individuals. We also report loci that confer susceptibility to both bipolar disorder and schizophrenia. The association near *MIR137*, associations in multiple predicted *MIR137* targets and the known role of *MIR137* in neuronal maturation and function together suggest an intriguing new insight into the pathogenesis of schizophrenia.

URLs

PLINK, <http://pngu.mgh.harvard.edu/~purcell/plink/>; Haploview, <http://www.broadinstitute.org/scientific-community/science/programs/medical-and-population-genetics/haploview/haploview>.

METHODS

Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturegenetics/>.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the study participants and the research staff at the many study sites. Over 40 US National Institutes of Health grants and similar numbers of government grants from other countries, along with substantial private and foundation support, enabled this work. We greatly appreciate the sustained efforts of T. Lehner (National Institute of Mental Health) on behalf of the Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium (PGC). Detailed acknowledgments, including grant support, are listed in the

References

1. Altshuler DM, et al. Integrating common and rare genetic variation in diverse human populations. *Nature*. 2010; 467:52–58. [PubMed: 20811451]

2. Barrett JC, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat Genet.* 2008; 40:955–962. [PubMed: 18587394]
3. Lango Allen H, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. *Nature.* 2010; 467:832–838. [PubMed: 20881960]
4. Purcell SM, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature.* 2009; 460:748–752. [PubMed: 19571811]
5. Price AL, et al. Discerning the ancestry of European Americans in genetic association studies. *PLoS Genet.* 2008; 4:e236. [PubMed: 18208327]
6. Devlin B, Roeder K. Genomic control for association studies. *Biometrics.* 1999; 55:997–1004. [PubMed: 11315092]
7. Dudbridge F, Gusnanto A. Estimation of significance thresholds for genomewide association scans. *Genet Epidemiol.* 2008; 32:227–234. [PubMed: 18300295]
8. Stefansson H, et al. Common variants conferring risk of schizophrenia. *Nature.* 2009; 460:744–747. [PubMed: 19571808]
9. Shi J, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. *Nature.* 2009; 460:753–757. [PubMed: 19571809]
10. Ferreira MA, et al. Collaborative genome-wide association analysis supports a role for *ANK3* and *CACNA1C* in bipolar disorder. *Nat Genet.* 2008; 40:1056–1058. [PubMed: 18711365]
11. Green EK, et al. The bipolar disorder risk allele at *CACNA1C* also confers risk of recurrent major depression and of schizophrenia. *Mol Psychiatry.* 2010; 15:1016–1022. [PubMed: 19621016]
12. Ruderfer DM, et al. A family-based study of common polygenic variation and risk of schizophrenia. *Mol Psychiatry.* April 12, 2011 published online. 10.1038/mp.2011.34
13. Bemis LT, et al. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. *Cancer Res.* 2008; 68:1362–1368. [PubMed: 18316599]
14. Srikantan V, et al. *PCGEM1*, a prostate-specific gene, is overexpressed in prostate cancer. *Proc Natl Acad Sci USA.* 2000; 97:12216–12221.
15. Szulwach KE, et al. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. *J Cell Biol.* 2010; 189:127–141. [PubMed: 20368621]
16. Silber J, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. *BMC Med.* 2008; 6:14. [PubMed: 18577219]
17. Smrt RD, et al. MicroRNA miR-137 regulates neuronal maturation by targeting ubiquitin ligase mind bomb-1. *Stem Cells.* 2010; 28:1060–1070. [PubMed: 20506192]
18. Potkin SG, et al. Identifying gene regulatory networks in schizophrenia. *Neuroimage.* 2010; 53:839–847. [PubMed: 20600988]
19. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell.* 2005; 120:15–20. [PubMed: 15652477]
20. Krek A, et al. Combinatorial microRNA target predictions. *Nat Genet.* 2005; 37:495–500. [PubMed: 15806104]
21. John B, et al. Human MicroRNA targets. *PLoS Biol.* 2004; 2:e363. [PubMed: 15502875]
22. Yang J, et al. Common SNPs explain a large proportion of the heritability for human height. *Nat Genet.* 2010; 42:565–569. [PubMed: 20562875]
23. Yang J, et al. Genomic inflation factors under polygenic inheritance. *Eur J Hum Genet.* 2011; 19:807–812. [PubMed: 21407268]
24. Visscher PM, Yang J, Goddard ME. A commentary on 'common SNPs explain a large proportion of the heritability for human height' by Yang *et al.* (2010). *Twin Res Hum Genet.* 2010; 13:517–524. [PubMed: 21142928]
25. Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease from genome-wide association studies. *Am J Hum Genet.* 2011; 88:294–305. [PubMed: 21376301]
26. Speliotes EK, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat Genet.* 2010; 42:937–948. [PubMed: 20935630]
27. Wei Z, et al. From disease association to risk assessment: an optimistic view from genome-wide association studies on type 1 diabetes. *PLoS Genet.* 2009; 5:e1000678. [PubMed: 19816555]

28. Bush WS, et al. Evidence for polygenic susceptibility to multiple sclerosis—the shape of things to come. *Am J Hum Genet.* 2010; 86:621–625. [PubMed: 20362272]
29. Lichtenstein P, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. *Lancet.* 2009; 373:234–239. [PubMed: 19150704]
30. Scott LJ, et al. Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. *Proc Natl Acad Sci USA.* 2009; 106:7501–7506. [PubMed: 19416921]

Appendix

Stephan Ripke¹, Alan R Sanders^{2,3}, Kenneth S Kendler^{4–6}, Douglas F Levinson⁷, Pamela Sklar^{1,8}, Peter A Holmans^{9,10}, Dan-Yu Lin¹¹, Jubao Duan^{2,3}, Roel A Ophoff^{12–15}, Ole A Andreassen^{16,17}, Edward Scolnick¹⁸, Sven Cichon^{19–21}, David St. Clair²², Aiden Corvin²³, Hugh Gurling²⁴, Thomas Werge²⁵, Dan Rujescu²⁶, Douglas H R Blackwood²⁷, Carlos N Pato²⁸, Anil K Malhotra^{29–31}, Shaun Purcell¹⁸, Frank Dudbridge³², Benjamin M Neale¹⁸, Lizzy Rossin¹, Peter M Visscher³³, Danielle Posthuma^{34,35}, Douglas M Ruderfer¹, Ayman Fanous^{5,36,37}, Hreinn Stefansson³⁸, Stacy Steinberg³⁸, Bryan J Mowry^{39,40}, Vera Golimbet⁴¹, Marc De Hert⁴², Erik G Jönsson⁴³, István Bitter⁴⁴, Olli P H

¹Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA.

²Department of Psychiatry and Behavioral Sciences, NorthShore University HealthSystem, Evanston, Illinois, USA.

³Department of Psychiatry and Behavioral Sciences, University of Chicago, Chicago, Illinois, USA.

⁴Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.

⁶Department of Human and Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.

⁷Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, USA.

⁸Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA.

⁹Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, UK.

¹⁰Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff, UK.

¹¹Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA.

¹²Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.

¹⁵Department of Human Genetics, University of California at Los Angeles, Los Angeles, California, USA.

¹⁶Psychiatry Section, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

¹⁷Department of Psychiatry, Oslo University Hospital, Oslo, Norway.

¹⁸Broad Institute, Cambridge, Massachusetts, USA.

¹⁹Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany.

²¹Institute of Human Genetics, University of Bonn, Bonn, Germany.

²²Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK.

²³Neuropsychiatric Genetics Research Group, Trinity College Dublin, Dublin, Ireland.

²⁴Molecular Psychiatry Laboratory, Research Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, London, UK.

²⁵Institute of Biological Psychiatry, Mental Health Center (MHC) Sct. Hans, Copenhagen University Hospital, Roskilde, Denmark.

²⁶Molecular and Clinical Neurobiology, Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany.

²⁷Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK.

²⁸Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

²⁹Department of Psychiatry, Division of Research, The Zucker Hillside Hospital Division of the North Shore-Long Island Jewish Health System, Glen Oaks, New York, USA.

³¹Department of Psychiatry and Behavioral Science, Albert Einstein College of Medicine of Yeshiva University, New York, New York, USA.

³²Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.

³³Queensland Statistical Genetics Laboratory, Queensland Institute of Medical Research, Brisbane, Queensland, Australia.

³⁴Vrije Universiteit (VU), Center for Neurogenetics and Cognitive Research (CNCR), Department of Functional Genomics, Amsterdam, The Netherlands.

³⁵VU Medical Centre, Department of Medical Genomics, Amsterdam, The Netherlands.

⁵Department of Psychiatry, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.

³⁶Washington Veteran's Affairs Medical Center, Washington, DC, USA.

³⁷Department of Psychiatry, Georgetown University School of Medicine, Washington, DC, USA.

³⁸deCODE Genetics, Reykjavik, Iceland.

³⁹Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia.

⁴⁰Queensland Centre for Mental Health Research, University of Queensland, Brisbane, Queensland, Australia.

⁴¹Mental Health Research Center, Russian Academy of Medical Sciences, Moscow, Russia.

⁴²University Psychiatric Centre, Catholic University Leuven, Kortenberg, Belgium.

⁴³Department of Clinical Neuroscience, Human Brain Informatics (HUBIN) Project, Karolinska Institutet and Hospital, Stockholm, Sweden.

Pietiläinen^{45, 46}, David A Collier⁴⁷, Sarah Tosato⁴⁸, Ingrid Agartz^{16, 49}, Margot Albus⁵⁰, Madeline Alexander⁷, Richard L Amdur^{36, 37}, Farooq Amin^{51, 52}, Nicholas Bass²⁴, Sarah E Bergen¹, Donald W Black⁵³, Anders D Børghlum^{54, 55}, Matthew A Brown⁵⁶, Richard Bruggeman⁵⁷, Nancy G Buccola⁵⁸, William F Byerley^{59, 60}, Wiepke Cahn⁶¹, Rita M Cantor^{14, 15}, Vaughan J Carr⁶², Stanley V Catts⁶³, Khalid Choudhury²⁴, C Robert Cloninger⁶⁴, Paul Cormican²³, Nicholas Craddock^{9, 10}, Patrick A Danoy⁵⁶, Susmita Datta²⁴, Lieuwe de Haan⁶⁵, Ditte Demontis⁵⁴, Dimitris Dikeos⁶⁶, Srdjan Djurovic^{16, 67}, Peter Donnelly^{68, 69}, Gary Donohoe²³, Linh Duong²⁵, Sarah Dwyer^{9, 10}, Anders Fink-Jensen⁷⁰, Robert Freedman⁷¹, Nelson B Freimer¹⁴, Marion Friedl²⁶, Lyudmila Georgieva^{9, 10}, Ina Giegling²⁶, Michael Gill²³, Birte Glenthøj⁷², Stephanie Godard⁷³, Marian Hamshere^{9, 10}, Mark Hansen⁷⁴, Thomas Hansen²⁵, Annette M Hartmann²⁶, Frans A Henskens⁷⁵, David M Hougaard⁷⁶, Christina M Hultman⁷⁷, Andrés Ingason²⁵, Assen V Jablensky⁷⁸, Klaus D Jakobsen²⁵, Maurice Jay^{79, 132}, Gesche Jürgens⁸⁰, René S Kahn⁶¹, Matthew C Keller⁸¹, Gunter Kenis⁸², Elaine Kenny²³, Yunjung Kim⁸³, George K

⁴⁴Semmelweis University, Department of Psychiatry and Psychotherapy, Budapest, Hungary.

⁴⁵Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.

⁴⁶Department of Medical Genetics, University of Helsinki, Helsinki, Finland.

⁴⁷Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College, London, UK.

⁴⁸Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy.

⁴⁹Department of Research, Diakonhjemmet Hospital, Oslo, Norway.

⁵⁰State Mental Hospital, Haar, Germany.

⁵¹Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia, USA.

⁵²Department of Psychiatry and Behavioral Sciences, Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, USA.

⁵³Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.

⁵⁴Institute of Human Genetics, University of Aarhus, Aarhus, Denmark.

⁵⁵Centre for Psychiatric Research, Aarhus University Hospital, Risskov, Denmark.

⁵⁶University of Queensland Diamantina Institute, Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia.

⁵⁷University Medical Center Groningen, Department of Psychiatry, University of Groningen, Groningen, The Netherlands.

⁵⁸School of Nursing, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.

⁵⁹Department of Psychiatry, University of California at San Francisco, San Francisco, California, USA.

⁶⁰NCIRE (Northern California Institute for Research and Education), San Francisco, California, USA.

⁶¹Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands.

¹⁴University of California at Los Angeles (UCLA) Center for Neurobehavioral Genetics, University of California at Los Angeles, Los Angeles, California, USA.

⁶²School of Psychiatry, University of New South Wales and Schizophrenia Research Institute, Sydney, New South Wales, Australia.

⁶³Department of Psychiatry, University of Queensland, Royal Brisbane Hospital, Brisbane, Australia.

⁶⁴Department of Psychiatry, Washington University, St. Louis, Missouri, USA.

⁶⁵Academic Medical Centre, University of Amsterdam, Department of Psychiatry, Amsterdam, The Netherlands.

⁶⁶Department of Psychiatry, University of Athens Medical School, Athens, Greece.

⁶⁷Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.

⁶⁸Wellcome Trust Centre for Human Genetics, Oxford, UK.

⁶⁹Department of Statistics, University of Oxford, Oxford, UK.

⁷⁰Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.

⁷¹Department of Psychiatry, University of Colorado Denver, Aurora, Colorado, USA.

⁷²Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Mental Health Center Glostrup, Copenhagen University Hospital, Glostrup, Denmark.

⁷³INSERM, Institut de Myologie, Hôpital de la Pitié-Salpêtrière, Paris, France.

⁷⁴Illumina, Inc., La Jolla, California, USA.

⁷⁵School of Electrical Engineering and Computing Science, University of Newcastle, Newcastle, New South Wales, Australia.

⁷⁶Section of Neonatal Screening and Hormones, Department of Clinical Chemistry and Immunology, The State Serum Institute, Copenhagen, Denmark.

⁷⁷Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

⁷⁸Centre for Clinical Research in Neuropsychiatry, School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Perth, Western Australia, Australia.

⁷⁹Department of Child and Adolescent Psychiatry, Pierre and Marie Curie Faculty of Medicine, Paris, France.

¹³²Deceased. Correspondence should be addressed to P.V.G. (pgejman@gmail.com).

⁸⁰Department of Clinical Pharmacology, Bispebjerg University Hospital, Copenhagen, Denmark.

⁸¹Department of Psychology, University of Colorado, Boulder, Boulder, Colorado, USA.

⁸²Department of Psychiatry and Psychology, School of Mental Health and Neuroscience, European Graduate School of Neuroscience (EURON), South Limburg Mental Health Research and Teaching Network (SEARCH), Maastricht University Medical Centre, Maastricht, The Netherlands.

⁸³Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Kirov^{9,10}, Heike Konnerth²⁶, Bettina Konte²⁶, Lydia Krabbendam⁸⁴, Robert Krasucki²⁴, Virginia K Lasseter^{85,132}, Claudine Laurent⁷⁹, Jacob Lawrence²⁴, Todd Lencz^{29,31}, F Bernard Lerer⁸⁶, Kung-Yee Liang⁸⁷, Paul Lichtenstein⁷⁷, Jeffrey A Lieberman⁸⁸, Don H Linszen⁶⁵, Jouko Lönnqvist⁸⁹, Carmel M Loughland⁹⁰, Alan W Maclean²⁷, Brion S Maher⁴⁻⁶, Wolfgang Maier⁹¹, Jacques Mallet⁹², Pat Malloy²⁷, Manuel Mattheisen^{19,21,93}, Morten Mattingsdal^{16,94}, Kevin A McGhee²⁷, John J McGrath^{39,40}, Andrew McIntosh²⁷, Duncan E McLean⁹⁵, Andrew McQuillin²⁴, Ingrid Melle^{16,17}, Patricia T Michie^{96,97}, Vihra Milanova⁹⁸, Derek W Morris²³, Ole Mors⁵⁵, Preben B Mortensen⁹⁹, Valentina Moskvina^{9,10}, Pierandrea Muglia^{100,101}, Inez Myin-Germeys⁸⁴, Deborah A Nertney^{39,40}, Gerald Nestadt⁸⁵, Jimmi Nielsen¹⁰², Ivan Nikolov^{9,10}, Merete Nordentoft¹⁰³, Nadine Norton^{9,10}, Markus M Nöthen^{19,21}, Colm T O'Dushlaine²³, Ann Olincy⁷¹, Line Olsen²⁵, F Anthony O'Neill¹⁰⁴, Torben F Ørntoft^{105,106}, Michael J Owen^{9,10}, Christos Pantelis¹⁰⁷, George Papadimitriou⁶⁶, Michele T Pato²⁸, Leena Peltonen^{45,46,108,132}, Hannes Petursson¹⁰⁹, Ben Pickard¹¹⁰, Jonathan Pimm²⁴, Ann E Pulver⁸⁵, Vinay Puri²⁴, Digby Quested¹¹¹, Emma M Quinn²³, Henrik B Rasmussen²⁵, János M Réthelyi⁴⁴, Robert Ribble⁴⁻⁶, Marcella Rietschel^{91,112}, Brien P Riley⁴⁻⁶, Mirella Ruggeri⁴⁸, Ulrich Schall^{97,113}, Thomas G Schulze^{112,114}, Sibylle G Schwab^{115,117}, Rodney J Scott¹¹⁸, Jianxin Shi¹¹⁹, Engilbert Sigurdsson^{109,120}, Jeremy M Silverman^{8,121}, Chris C A

⁸⁴Maastricht University Medical Centre, South Limburg Mental Health Research and Teaching Network, Maastricht, The Netherlands.

⁸⁵Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

⁸⁶Department of Psychiatry, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

⁸⁷Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.

⁸⁸Department of Psychiatry, Columbia University, New York, New York, USA.

⁸⁹Department of Mental Health and Substance Abuse Services, National Institute for Health and Welfare, Helsinki, Finland.

⁹⁰Schizophrenia Research Institute, Sydney and Centre for Brain and Mental Health Research, University of Newcastle, Newcastle, New South Wales, Australia.

⁹¹Department of Psychiatry, University of Bonn, Bonn, Germany.

⁹²Laboratoire de Génétique Moléculaire de la Neurotransmission et des Processus Neurodégénératifs, Centre National de la Recherche Scientifique, Hôpital de la Pitié Salpêtrière, Paris, France.

⁹³Institute of Medical Biometry, Informatics and Epidemiology (IMBIE), University of Bonn, Bonn, Germany.

⁹⁴Department of Research, Sørlandet Hospital, Kristiansand, Norway.

⁹⁵Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol, Queensland, Australia.

⁹⁶Functional NeuroImaging Laboratory, School of Psychology, University of Newcastle, Sydney, New South Wales, Australia.

⁹⁷Schizophrenia Research Institute, Sydney, New South Wales, Australia.

⁹⁸Department of Psychiatry, First Psychiatric Clinic, Alexander University Hospital, Sofia, Bulgaria.

⁹⁹National Centre for Register-Based Research, University of Aarhus, Aarhus, Denmark.

¹⁰⁰Department of Psychiatry, University of Toronto, Toronto, Canada.

¹⁰¹NeuroSearch A/S, Ballerup, Denmark.

¹⁰²Unit for Psychiatric Research, Aalborg Psychiatric Hospital, Aalborg, Denmark.

¹⁰³Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.

¹⁰⁴Department of Psychiatry, Queens University, Belfast, Ireland.

¹⁰⁵ARoS Applied Biotechnology A/S, Skejby, Denmark.

¹⁰⁶Department of Molecular Medicine, Aarhus University Hospital, Skejby, Denmark.

¹⁰⁷Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Melbourne, Victoria, Australia.

¹⁰⁸Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.

¹⁰⁹Department of Psychiatry, National University Hospital, Reykjavik, Iceland.

¹¹⁰Strathclyde Institute of Pharmacy and Biomedical Sciences, The John Arbuthnott Building, University of Strathclyde, Glasgow, UK.

¹¹¹Department of Psychiatry, University of Oxford, Warneford Hospital, Headington, Oxford, UK.

¹¹²Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.

¹¹³Priority Centre for Brain and Mental Health Research, University of Newcastle, Sydney, New South Wales, Australia.

¹¹⁴Department of Psychiatry and Psychotherapy, Georg-August-University, Göttingen, Germany.

¹¹⁵School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Western Australia, Australia.

¹¹⁷Centre for Medical Research, Western Australian Institute for Medical Research, University of Western Australia, Perth, Western Australia, Australia.

¹¹⁸Centre for Information Based Medicine, University of Newcastle, Hunter Medical Research Institute, Newcastle and Schizophrenia Research Institute, Sydney, New South Wales, Australia.

¹¹⁹Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.

¹²⁰Department of Psychiatry, University of Iceland, Reykjavik, Iceland.

Spencer⁶⁸, Kari Stefansson³⁸, Amy Strange⁶⁸, Eric Strengman^{12,13}, T Scott Stroup⁸⁸, Jaana Suvisaari⁸⁹, Lars Terenius⁴³, Srinivasa Thirumalai¹²², Johan H Thygesen²⁵, Sally Timm¹²³, Draga Toncheva¹²⁴, Edwin van den Oord¹²⁵, Jim van Os⁸⁴, Ruud van Winkel^{42,82}, Jan Veldink¹²⁶, Dermot Walsh¹²⁷, August G Wang¹²⁸, Durk Wiersma⁵⁷, Dieter B Wildenauer^{115,129}, Hywel J Williams^{9,10}, Nigel M Williams^{9,10}, Brandon Wormley⁴⁻⁶, Stan Zammit^{9,10}, Patrick F Sullivan^{77,83,130,131}, Michael C O'Donovan^{9,10}, Mark J Daly¹ & Pablo V Gejman^{2,3}

¹²¹Department of Psychiatry, Veterans Affairs Medical Center, New York, New York, USA.

¹³Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands.

¹²²West Berkshire National Health Service (NHS) Trust, Reading, UK.

¹²³Mental Health Center Frederiksberg, Copenhagen University Hospital, Copenhagen, Denmark.

¹²⁴Department of Medical Genetics, University Hospital Maichin Dom, Sofia, Bulgaria.

¹²⁵Department of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA.

¹²⁶Rudolf Magnus Institute of Neuroscience, Department of Neurology, Universitair Medisch Centrum (UMC) Utrecht, Utrecht, The Netherlands.

¹²⁷The Health Research Board, Dublin, Ireland.

¹²⁸Mental Health Center Amager, Copenhagen University Hospital, Copenhagen, Denmark.

¹²⁹Centre for Clinical Research in Neuropsychiatry, Graylands Hospital, Mt Claremont, Western Australia, Australia.

¹³⁰Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

¹³¹Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.




Figure 1.

Manhattan plot for stages 1 and 2. Standard $-\log_{10} P$ plot of the study results. For the stage 1 results, 16 regions with one or more SNP achieving $P < 10^{-6}$ are highlighted in color and labeled with the name of the nearest gene. SNPs selected for stage 2 replication are highlighted, with the resulting combined P value after replication (that is, after incorporation of stage 2 results) indicated by the large diamonds. Blue highlighting indicates SNPs that were less significantly associated after replication, and pink highlighting indicates SNPs that were more significantly associated after replication.




Figure 2. Regional association plots for five new schizophrenia loci. Regional P value plots for each of the five new schizophrenia loci: 1p21.3, 2q32.3, 8p23.2, 8q21.3 and 10q24.32-q24.33. Each plot shows the most associated SNP (key SNP) and its genomic region from the first column of Table 2: stage 1 scan results for each SNP ± 200 kb to the key SNP are shown. On the x axis is the genomic position, and on the y axis is $-\log_{10} P$. Larger SNP symbols indicate higher LD (based on HapMap 3 data) to the key SNP than smaller SNP symbols. Color coding (from red to blue) denotes LD information; see also the legend within the plot.

Table 1

Study design and samples

| Collection | Country | Platform | Cases included by sex | | | Controls included by sex | | | Total | |
|----------------------------------|----------------------------------|---------------------------------|-----------------------|--------------|----------|--------------------------|--------------|--------------|----------|---------------|
| | | | Male | Female | Unknown | Male | Female | Unknown | | |
| Cardiff UK | UK | Affymetrix 500K | 320 | 152 | 0 | 472 | 1,442 | 1,492 | 0 | 2,934 |
| CATIE | United States | Affymetrix 500K; Perlegen 164K | 308 | 94 | 0 | 402 | 161 | 46 | 0 | 207 |
| ISC-Aberdeen | UK | Affymetrix 5.0 | 536 | 184 | 0 | 720 | 447 | 251 | 0 | 698 |
| ISC-Cardiff | Bulgaria | Affymetrix 6.0 | 270 | 257 | 0 | 527 | 291 | 318 | 0 | 609 |
| ISC-Dublin | Ireland | Affymetrix 6.0 | 188 | 82 | 0 | 270 | 258 | 602 | 0 | 860 |
| ISC-Edinburgh | UK | Affymetrix 6.0 | 267 | 101 | 0 | 368 | 146 | 138 | 0 | 284 |
| ISC-London | UK | Affymetrix 5.0; Affymetrix 500K | 369 | 149 | 0 | 518 | 207 | 284 | 0 | 491 |
| ISC-Portugal | Portugal | Affymetrix 5.0 | 213 | 133 | 0 | 346 | 80 | 135 | 0 | 215 |
| ISC-SW1 | Sweden | Affymetrix 5.0 | 93 | 75 | 0 | 168 | 82 | 85 | 0 | 167 |
| ISC-SW2 | Sweden | Affymetrix 6.0 | 231 | 159 | 0 | 390 | 116 | 113 | 0 | 229 |
| MGS | United States, Australia | Affymetrix 6.0 | 1,863 | 816 | 0 | 2,679 | 1,140 | 1,344 | 0 | 2,484 |
| SGENE-Bonn | Germany | Illumina 550K | 238 | 236 | 0 | 474 | 664 | 640 | 0 | 1,304 |
| SGENE-Copenhagen | Denmark | Illumina Human 610-Quad | 280 | 202 | 0 | 482 | 268 | 189 | 0 | 457 |
| SGENE-Munich | Germany | Illumina 300K | 279 | 155 | 0 | 434 | 167 | 184 | 0 | 351 |
| SGENE-TOP3 | Norway | Affymetrix 6.0 | 132 | 116 | 0 | 248 | 176 | 175 | 0 | 351 |
| SGENE-UCLA | The Netherlands | Illumina 550K | 529 | 175 | 0 | 704 | 310 | 321 | - | 631 |
| Zucker Hillside | United States | Affymetrix 500K | 128 | 64 | 0 | 192 | 92 | 98 | 0 | 190 |
| Grand totals for the GWAs | | | 6,244 | 3,150 | 0 | 9,394 | 6,047 | 6,415 | - | 12,462 |
| Multicenter Pedigree | Europe, United States, Australia | Illumina Human 610-Quad | n.a. | n.a. | 0 | 583 | 0 | 0 | 0 | 0 |
| SGENE-Aarhus | Denmark | Illumina Human 610-Quad | 477 | 399 | 0 | 876 | 477 | 397 | 0 | 874 |
| SGENE-Aarhus | Denmark | Centaurus | 114 | 102 | 1 | 217 | 176 | 317 | 0 | 493 |
| SGENE-Belgium | Belgium | Centaurus; Illumina 370K | 326 | 184 | 0 | 510 | 149 | 192 | 0 | 341 |
| SGENE-Copenhagen | Denmark | Centaurus | 264 | 198 | 0 | 462 | 499 | 375 | 0 | 874 |
| SGENE-Iceland | Iceland | Illumina 300K | 346 | 185 | 0 | 531 | 5,802 | 5,813 | 0 | 11,615 |
| SGENE-England | UK | Illumina 300K | 71 | 22 | 0 | 93 | 48 | 40 | 0 | 88 |
| SGENE-Helsinki | Finland | Illumina 300K | 112 | 70 | 0 | 59 | 122 | 75 | 0 | 147 |
| SGENE-Kuusamo | Finland | Illumina 300K | | | | 123 | | | | 50 |

| Collection | Country | Platform | Cases included by sex | | | Controls included by sex | | | Total | |
|---|-----------|-------------------|-----------------------|--------------|-----------|--------------------------|---------------|---------------|-----------|---------------|
| | | | Male | Female | Unknown | Male | Female | Unknown | | |
| SGENE-Hungary | Hungary | Centaurus | 105 | 136 | 0 | 241 | 89 | 125 | 0 | 214 |
| SGENE-Italy | Italy | Illumina 300K | 48 | 36 | 0 | 84 | 50 | 39 | 0 | 89 |
| SGENE-Munich | Germany | Illumina 300K | 280 | 186 | 0 | 163 | 887 | 912 | 0 | 185 |
| SGENE-Munich | Germany | Centaurus | | | | 303 | | | | 1,614 |
| SGENE-Russia | Russia | Centaurus | 132 | 343 | 0 | 475 | 178 | 290 | 0 | 468 |
| SGENE-Sweden | Sweden | Centaurus | 158 | 94 | 0 | 252 | 178 | 109 | 0 | 287 |
| SW3 | Sweden | Affymetrix 6.0 | 327 | 212 | 0 | 539 | 457 | 448 | 0 | 905 |
| SW4 | Sweden | Affymetrix 6.0 | 656 | 407 | 0 | 1,063 | 605 | 568 | 0 | 1,173 |
| UQ and ASRB | Australia | SequenomMassArray | 347 | 190 | 21 | 558 | 487 | 455 | 15 | 957 |
| ISGC and WTCCC2 | Ireland | Affymetrix 6.0 | 968 | 342 | 0 | 1,310 | 245 | 778 | 0 | 1,023 |
| Grand totals for the replication follow up | | | 4,731 | 3,106 | 22 | 8,442 | 10,449 | 10,933 | 15 | 21,397 |

Stage 1 describes the 17 samples that provided full GWAS genotyping data, and stage 2 describes the 19 studies that provided results for the top SNPs identified in the combined analysis of stage 1 studies. Stage 2 replication SGENE-Belgium had four cases missing sex information. Stage 2 replication SGENE-Aarhus (focused genotyping sample) had one case missing sex information. Stage 2 replication-University of Queensland had 21 cases and 15 controls missing sex information. Sex information for the two stage 2 replication SGENE-Munich samples are combined. Sex information for the two stage 2 replication SGENE-Finnish (Helsinki and Kuusamo) samples are combined to enable that these two samples are located adjacent to each other in the table (rather than alphabetically). Multicenter Pedigree was a family sample, and so case sex counts are not applicable (n.a.). SGENE, Schizophrenia Genetics Consortium; ISC, International Schizophrenia Consortium; TOP3, Thematic Organized Psychoses Research 3; UCLA, University of California at Los Angeles; SW1, Sweden 1; SW2, Sweden 2; WTCCC, Wellcome Trust case Control Consortium; for the Multicenter Pedigree study, the number of cases indicates the number of families; CATIE, Clinical Antipsychotic Trials of Intervention Effectiveness; MGS, Molecular Genetics of Schizophrenia; UQ, University of Queensland; ASRB, Australian Schizophrenia Research Bank; ISGC, Irish Schizophrenia Genomics Consortium.

Table 2

Top genome-wide association results for schizophrenia

| SNP | Chr. | Mb | Alleles | Frequency | <i>P</i> (GC-adjusted <i>P</i>) | OR (95% CI) | Consistency of direction | Gene | Distance (kb) |
|------------|-----------------------|-------|---------|-----------|---|------------------|--------------------------|---------------|---------------|
| rs1625579 | 1p21.3 ^a | 98.3 | TG | 0.80 | 5.72×10^{-7} (6.52×10^{-6}) | 1.14 (1.08–1.19) | + + + + + + - + | <i>MIR137</i> | Intragenic |
| rs17662626 | 2q32.3 ^a | 193.7 | AG | 0.91 | 1.59×10^{-11} (6.87×10^{-10}) | 1.12 (1.09–1.16) | + - + + + + - + | <i>PCGEM1</i> | 343 |
| rs2021722 | 6p21.3-p22.1 | 30.3 | CT | 0.78 | 3.09×10^{-6} (2.60×10^{-5}) | 1.22 (1.13–1.30) | + - + + + + + + | <i>TRIM26</i> | Intragenic |
| rs10503253 | 8p23.2 ^a | 4.2 | AC | 0.19 | 4.65×10^{-8} (1.25×10^{-6}) | 1.20 (1.13–1.26) | + + + - + + | <i>C5MD1</i> | Intragenic |
| rs7004633 | 8q21.3 ^a | 89.8 | GA | 0.18 | 4.30×10^{-11} (2.76×10^{-9}) | 1.18 (1.13–1.23) | + + + + + + - + | <i>MMP16</i> | 421 |
| rs7914558 | 10q24.32 ^a | 104.8 | GA | 0.59 | 2.18×10^{-12} (2.88×10^{-10}) | 1.15 (1.11–1.19) | + + + + + + - + | <i>CNNM2</i> | Intragenic |
| rs11191580 | 10q24.33 ^a | 104.9 | TC | 0.91 | 3.84×10^{-7} (4.71×10^{-6}) | 1.14 (1.09–1.19) | + + + + + + - + | <i>NT5C2</i> | Intragenic |
| rs548181 | 11q24.2 | 125.0 | GA | 0.88 | 4.14×10^{-8} (8.98×10^{-7}) | 1.11 (1.07–1.15) | + + + + + + - + | <i>S7T3A</i> | 1 |
| rs12966547 | 18q21.2 | 50.9 | GA | 0.58 | 2.75×10^{-8} (7.03×10^{-7}) | 1.10 (1.07–1.14) | + + + + + + - + | <i>CCDC68</i> | 126 |
| | | | | | 1.58×10^{-7} (2.27×10^{-6}) | 1.11 (1.07–1.15) | + + + + + + - + | | |
| | | | | | 1.82×10^{-9} (3.11×10^{-8}) | 1.10 (1.07–1.13) | + + + + + + - + | | |
| | | | | | 2.23×10^{-8} (4.58×10^{-7}) | 1.22 (1.15–1.29) | + + + + + + - + | | |
| | | | | | 5.09×10^{-3} (n.a.) | 1.09 (1.02–1.16) | + + + + + + - + | | |
| | | | | | 1.11×10^{-8} (3.72×10^{-7}) | 1.15 (1.10–1.20) | + + + + + + - + | | |
| | | | | | 2.91×10^{-8} (5.69×10^{-7}) | 1.20 (1.13–1.26) | + + + + + + - + | | |
| | | | | | 0.068 (n.a.) | 1.04 (0.98–1.11) | + + + + + + - + | | |
| | | | | | 8.87×10^{-7} (1.74×10^{-5}) | 1.11 (1.07–1.16) | + + + + + + - + | | |
| | | | | | 1.00×10^{-6} (1.03×10^{-5}) | 1.10 (1.06–1.14) | + + + + + + - + | | |
| | | | | | 2.29×10^{-5} (n.a.) | 1.08 (1.04–1.12) | + + + + + + - + | | |
| | | | | | 2.60×10^{-10} (5.99×10^{-9}) | 1.09 (1.06–1.12) | + + + + + + - + | | |

| SNP | Chr. | Mb | Alleles | Frequency | <i>P</i> (GC-adjusted <i>P</i>) | OR (95% CI) | Consistency of direction | Gene | Distance (kb) |
|------------|---------|------|---------|-----------|---|------------------|--------------------------|-------------|---------------|
| rs17512836 | 18q21.2 | 51.3 | CT | 0.02 | 2.35×10^{-8} (4.78×10^{-7}) | 1.40 (1.28–1.52) | +++++++ | <i>TCF4</i> | Intragenic |
| | | | | | 0.085 (n.a.) | 1.08 (0.96–1.20) | | | |
| | | | | | 1.05×10^{-6} (2.86×10^{-5}) | 1.23 (1.14–1.31) | | | |

The SNPs listed are those with a stage 1 $P < 5 \times 10^{-8}$ and/or a combined stage 1 and 2 $P < 5 \times 10^{-8}$. These ten independent ($r^2 < 0.2$) SNPs represent eight physically distinct genomic loci, as there are two SNPs listed for two loci (10q24.32-q24.33 and 18q21.2). For the MHC region, only one SNP is listed for clarity. The eight susceptibility loci represent three previously reported and five new loci (Supplementary Table 7). Stage 1 is the discovery GWAS mega-analysis. Stage 2 is the replication sample (single-tailed meta-analysis, *P* values are weighted by 1/s.e.), and because the *P* values are single tailed, some 95% confidence intervals contain 1 (if $0.10 < P < 0.05$). Combined values include stages 1 and 2 (two-tailed meta-analysis, *P* values are weighted by 1/s.e.). For each SNP, *P* values and odds ratios are listed for stage 1 (top), stage 2 (middle) and combined stage 1 and 2 analysis (bottom) with the genomic control (GC)-adjusted values bracketed (n.a., not applicable for stage 2). Alleles are listed with the stage 1 risk allele first; the frequency (in stage 1 controls) and odds ratio (OR) refer to the stage 1 risk allele. Bolded *P* values indicate $P < 5 \times 10^{-8}$, except for in the stage 2 data, where bolded values indicate $P < 0.05$. The directions of association in eight replication samples are represented by + if the associations are in the same direction, – if they are in opposite directions; and a blank space if the data are not available. Mb is the base position based on hg18. Cytogenetic bands are listed for each SNP, though because only one of multiple MHC SNPs are listed, a band range is given in that instance. The nearest gene (or microRNA) is listed, with the distance (kb) from the gene (or if the SNP is intragenic) noted. None of these SNPs showed a significant test for heterogeneity among the samples. Chr., chromosome.

^dNew finding.